Julie M. Silverstein, MD

Division of Endocrinology, Metabolism and Lipid Research, Department of Neurosurgery, Washington University School of Medicine
St. Louis, Missouri, United States

Disclosure information not submitted.

Presentation(s):

• MON-036 - Long-Term Safety and Efficacy of CAM2029 in Patients with Acromegaly: Results from the ACROINNOVA 2 Open-Label Extension

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT

• MON-038 - Long-Term CAM2029 Octreotide Depot Maintains Biochemical and Symptom Control in Acromegaly Across A 4-Week Dosing Interval and during Intervals >28 Days: Data from the ACROINNOVA 2 Trial

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT

• MON-036 - Long-Term Safety and Efficacy of CAM2029 in Patients with Acromegaly: Results from the ACROINNOVA 2 Open-Label Extension

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT

• MON-038 - Long-Term CAM2029 Octreotide Depot Maintains Biochemical and Symptom Control in Acromegaly Across A 4-Week Dosing Interval and during Intervals >28 Days: Data from the ACROINNOVA 2 Trial

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT